Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9255960 | 0.83 | DRD2 (0.51) | TBXA2RDRD2DRD3HTR6PLAU | |
| SCHEMBL15078827 | 0.82 | ALDH1A1 (0.55) | TBXA2RDRD2DRD3HTR6 | |
| SCHEMBL1682787 | 0.80 | DRD2 (0.56) | TBXA2RDRD2DRD3HTR6PLAU | |
| SCHEMBL2485216 | 0.80 | DRD2 (0.56) | TBXA2RDRD2DRD3HTR6PLAU | |
| SCHEMBL7554445 | 0.79 | DRD2 (0.63) | DRD2DRD3HTR6PLAU | |
| SCHEMBL24650333 | 0.79 | S1PR5 (0.44) | TBXA2RDRD2DRD3S1PR5PTGER1 | |
| SCHEMBL2486276 | 0.78 | DRD2 (0.48) | TBXA2RDRD2DRD3HTR6PLAU | |
| SCHEMBL24650340 | 0.78 | S1PR5 (0.41) | TBXA2RDRD2DRD3S1PR5 | |
| Bromide SCHEMBL2482900 | 0.77 | DRD2 (0.47) | TBXA2RDRD2DRD3HTR6PLAU | |
| SCHEMBL7772422 | 0.74 | PTGIR (0.60) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012015944-A2 | NOVEL TETRAHYDRONAPHALENE ANTAGONISTS TO THE THROMBOXANE A2 (TP) RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-0648741-B1 | 1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents | ADIR (FR) | 1996-12-18 | — | — | EP | disclosed |
| EP-0648741-A1 | 1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents | ADIR ET COMPAGNIE (FR) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | TBXA2R, PTGIR, PTGFR | TBXA2R 1/4885DRD2 1052/4885DRD3 1957/4885 |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | TBXA2R, TBXAS1, PTGIR | TBXA2R 1/4885DRD2 676/4885DRD3 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.